Skip to content

Revision Total Hip Replacement Arthroplasty and Hematologic Variables

Relations Between Hematologic Variables and Postoperative Bleeding and Transfusion in Revision Total Hip Replacement Arthroplasty

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02951741
Enrollment
62
Registered
2016-11-01
Start date
2015-04-30
Completion date
2017-02-28
Last updated
2017-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Avascular Necrosis of Hip, Degenerative Hip Joint Disease

Brief summary

Revision total hip replacement arthroplasty is a surgery having intra- and postoperative substantial blood loss. The investigators will investigate the relationship between the various hematologic variables and postoperative bleeding volume.

Interventions

OTHERRTHRA group

hematologic variables measurement in patients undergoing revision total hip replacement

Sponsors

Seoul National University Bundang Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* revision total hip replacement

Exclusion criteria

* hematologic disease * anticoagulant medication * American Society of Anesthesiologists physical status 4 and 5

Design outcomes

Primary

MeasureTime frameDescription
Change of FIBTEM5 minutes before initiation of anesthesia and 5 minutes after finishing operationFIBTEM: one of the measurements of the rotational thromboelastometry

Secondary

MeasureTime frameDescription
intraoperative urine outputPeriod from starting to finishing the operation (During operation, an expected average of 3 hours)
transfusion unitsPeriod from starting to finishing the operation (During operation, an expected average of 3 hours) and postoperative first dayRed blood cell
postoperative bleeding volumepostoperative 72 hours
Hemoglobinpreoperative day 1
volume of infused fluid during operationPeriod from starting to finishing the operation (During operation, an expected average of 3 hours)Infused total crystalloid and colloid volume during the operation will be recorded
Platelet countpreoperative day 1
prothrombin time_international normalized ratiopreoperative day 1
activated partial prothrombin timepreoperative day 1
fibrinogen concentrationpreoperative day 1
Hematocritpreoperative day 1

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026